Dena M. Carbonari

J. Roy, J. Kostman, K. Reddy, 2016, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

HIV RNA, CD4+ Percentage, and Risk of Hepatocellular Carcinoma by Cirrhosis Status.

J. Roy, A. Justice, M. Kallan, 2019, Journal of the National Cancer Institute.

Determinants of Liver Complications Among HIV/Hepatitis B Virus-Coinfected Patients

Richard D Moore, J. Roy, J. Kostman, 2019, Journal of acquired immune deficiency syndromes.

Differences in Pathology, Staging, and Treatment between HIV+ and Uninfected Patients with Microscopically Confirmed Hepatocellular Carcinoma

R. Homer, A. Justice, M. Kallan, 2019, Cancer Epidemiology, Biomarkers & Prevention.

Absolute Insurer Denial of Direct-Acting Antiviral Therapy for Hepatitis C: A National Specialty Pharmacy Cohort Study

J. Roy, J. Kostman, C. Gowda, 2018, Open forum infectious diseases.

Risk of Acute Liver Failure in Patients With Drug-Induced Liver Injury: Evaluation of Hy's Law and a New Prognostic Model.

J. Roy, B. Strom, K. Reddy, 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Evaluation of methods to estimate missing days’ supply within pharmacy data of the Clinical Practice Research Datalink (CPRD) and The Health Improvement Network (THIN)

J. Roy, A. Gallagher, Harshvinder Bhullar, 2016, European Journal of Clinical Pharmacology.

Safety of saxagliptin: rationale for and design of a series of postmarketing observational studies

D. Margolis, S. Kimmel, J. Roy, 2012, Pharmacoepidemiology and drug safety.

Validity of diagnostic codes and laboratory tests of liver dysfunction to identify acute liver failure events

J. Roy, B. Strom, J. Lewis, 2015, Pharmacoepidemiology and drug safety.

Determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugs

J. Roy, B. Strom, S. Hennessy, 2015, BMC Pharmacology and Toxicology.

Prevalence of diagnosed chronic hepatitis B infection among U.S. Medicaid enrollees, 2000-2007.

J. Kostman, S. Hennessy, M. Leonard, 2014, Annals of epidemiology.

Validity of ICD‐10‐CM diagnoses to identify hospitalizations for serious infections among patients treated with biologic therapies

Charles E. Leonard, Jennifer G. Lyons, D. Graham, 2021, Pharmacoepidemiology and drug safety.

Brief Report: Accuracy of FIB-4 for Cirrhosis in People Living With HIV and Hepatocellular Carcinoma.

A. Justice, M. Kallan, T. Taddei, 2020, Journal of acquired immune deficiency syndromes.

Postauthorization safety study of the DPP-4 inhibitor saxagliptin: a large-scale multinational family of cohort studies of five outcomes

D. Margolis, S. Kimmel, J. Roy, 2017, BMJ Open Diabetes Research & Care.

Concordance of hospitalizations between Clinical Practice Research Datalink and linked Hospital Episode Statistics among patients treated with oral antidiabetic therapies

B. Strom, S. Hennessy, J. Wood, 2019, Pharmacoepidemiology and drug safety.

Validity of diagnostic codes to identify hospitalizations for infections among patients treated with oral anti‐diabetic drugs

J. Roy, B. Strom, A. Gallagher, 2018, Pharmacoepidemiology and drug safety.

Use of demographic and pharmacy data to identify patients included within both the Clinical Practice Research Datalink (CPRD) and The Health Improvement Network (THIN)

J. Roy, B. Strom, S. Hennessy, 2015, Pharmacoepidemiology and drug safety.

Determinants of saxagliptin use among patients with type 2 diabetes mellitus treated with oral anti-diabetic drugs

J. Roy, B. Strom, S. Hennessy, 2015, BMC Pharmacology and Toxicology.

Validity of diagnostic codes to identify cases of severe acute liver injury in the U.S. Food and Drug Administration's Mini‐Sentinel Distributed Database

Sengwee Toh, Kevin Haynes, Sean Hennessy, 2013, Pharmacoepidemiology and drug safety.

Protease inhibitor-based direct-acting antivirals are associated with increased risk of aminotransferase elevations but not hepatic dysfunction or decompensation.

C. Rentsch, A. Justice, T. Taddei, 2021, Journal of hepatology.

Risk of HCC With Hepatitis B Viremia Among HIV/HBV‐Coinfected Persons in North America

Richard D Moore, J. Roy, J. Kostman, 2021, Hepatology.

Disparities in Absolute Denial of Modern Hepatitis C Therapy by Type of Insurance.

J. Roy, J. Kostman, K. Reddy, 2016, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Hepatitis B care cascade among people with HIV/HBV coinfection in the North American AIDS Cohort Collaboration on Research and Design, 2012–2016

Jun Yu Li, S. Gange, J. Willig, 2023, PloS one.

Risk of admission to hospital with arterial or venous thromboembolism among patients diagnosed in the ambulatory setting with covid-19 compared with influenza: retrospective cohort study

Maria E. Kempner, C. Steiner, R. Hubbard, 2023, BMJ medicine.

Risk of Arterial and Venous Thrombotic Events Among Patients with COVID-19: A Multi-National Collaboration of Regulatory Agencies from Canada, Europe, and United States

Maria E. Kempner, N. Cocoros, E. Burn, 2024, Clinical epidemiology.